Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 136

Sort by

Sort Order Select

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data

Jan-Niklas Eckardt, Ishan Srivastava, Yeqiao Xu, Kellen B Gil, Andrea A. Osypuk, Zenggang Pan, Martin M. K. Schneider, Freya Schulze, Karsten Wendt, Susann Winter, Martin Bornhäuser, Daniel A. Pollyea, Jan Moritz Middeke

Blood (2024) 144 (Supplement 1): 2917.

https://doi.org/10.1182/blood-2024-206776

Published: 2024

Journal Articles

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Curtis A Lachowiez, Daniel T Peters, Jacob Fang, Andy Kaempf, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner, Joshua F Zeidner, Daniel A Pollyea, Jennifer N. Saultz

Blood (2024) 144 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2024-202118

Published: 2024

Journal Articles

STAT3-VDAC1 Axis Modulates Mitochondrial Function and Plays a Critical Role in the Survival of Leukemic Stem Cells

Kellen B Gil, Jamie Borg, Rosana Moreira Pereira, Anagha Inguva Sheth, Jeremy Rahkola, William Showers, Angelo D'Alessandro, Christine M. McMahon, Daniel A Pollyea, Austin E Gillen, Maria L Amaya

Blood (2024) 144 (Supplement 1): 2722.

https://doi.org/10.1182/blood-2024-207887

Published: 2024

Journal Articles

Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)

Cassandra Duarte, Diana Abbott, Christine M. McMahon, Andrew Kent, Marc Schwartz, Jonathan Gutman, Daniel A Pollyea, Maria L Amaya

Blood (2024) 144 (Supplement 1): 3803.

https://doi.org/10.1182/blood-2024-201061

Published: 2024

Journal Articles

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Vishvaas I Ravikumar, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Mael Heiblig, Joshua F Zeidner, Daniel A Pollyea, Curtis A Lachowiez

Blood (2024) 144 (Supplement 1): 4312.

https://doi.org/10.1182/blood-2024-201231

Published: 2024

Journal Articles

Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia

Jason S. Gilbert, Megan Connor, Grace Bosma, Christine M. McMahon, Maria L Amaya, Jonathan Gutman, Marc Schwartz, Andrew Kent, Diana Abbott, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 4266.

https://doi.org/10.1182/blood-2024-199862

Published: 2024

Journal Articles

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Maria L Amaya, Christine M. McMahon, Marc Schwartz, Jonathan Gutman, Andrew Kent, Diana Abbott, Connor Sohalski, Jessica Dell-Martin, Ayele Belachew, Brett M Stevens, Craig T Jordan, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 4259.

https://doi.org/10.1182/blood-2024-202839

Published: 2024

Journal Articles

Comparison of Myeloablative Conditioning with a Total Body Irradiation-Based Regimen Versus a Chemotherapy-Based Regimen in Adult Patients Undergoing Umbilical Cord Blood Stem Cell Transplant for Ph-Negative Acute Lymphoblastic Leukemia

Jason S. Gilbert, Andrew Kent, Jonathan Gutman, Maria L Amaya, Christine M. McMahon, Daniel A Pollyea, Marc Schwartz

Blood (2024) 144 (Supplement 1): 7280.

https://doi.org/10.1182/blood-2024-200993

Published: 2024

Journal Articles

Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML

Curtis A Lachowiez, Joshua F Zeidner, Ashley M. Eckel, Daniel T Peters, Jacob Fang, Amenech Ashango, Andy Kaempf, Fangyan Dai, Christopher A. Eide, Stephen E. Kurtz, Theodore P Braun, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 62.

https://doi.org/10.1182/blood-2024-201532

Published: 2024

Journal Articles

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Blood (2024) 144 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2024-206538

Published: 2024

Journal Articles

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 969.

https://doi.org/10.1182/blood-2024-199267

Published: 2024

Journal Articles

Treatment-Related and De Novo Ccus Have Similar Molecular Features and Risk of Progression to Myeloid Malignancies

Jennifer Santos, Diana Abbott, Grace Bosma, Andrew Kent, Marc Schwartz, Christine M. McMahon, Jonathan Gutman, Daniel A Pollyea, Maria L Amaya

Blood (2024) 144 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2024-201062

Published: 2024

Journal Articles

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Blood (2024) 144 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2024-199336

Published: 2024

Journal Articles

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A. Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N. Saultz, Jeffrey W. Tyner, Richard James Dillon, Joshua F. Zeidner, Daniel A. Pollyea

Blood blood.2024026925.

https://doi.org/10.1182/blood.2024026925

Published: 2024

Includes: Supplemental data

Journal Articles

Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Blood (2023) 142 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2023-173283

Published: 2023

Journal Articles

Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia

Maria L Amaya, Christine M. McMahon, Marc Schwartz, Jonathan A Gutman, Connor Sohalski, Jennifer Tobin, Austin E Gillen, Anagha Inguva Sheth, Brett M Stevens, Clayton Smith, Craig T. Jordan, Daniel A. Pollyea

Blood (2023) 142 (Supplement 1): 2914.

https://doi.org/10.1182/blood-2023-182966

Published: 2023

Journal Articles

Targeting Mitochondrial Calcium Uptake to Eradicate Venetoclax-Resistant Acute Myeloid Leukemia Stem Cells

Blood (2023) 142 (Supplement 1): 588.

https://doi.org/10.1182/blood-2023-188285

Published: 2023

Journal Articles

Age-Adapted Chemotherapy for Adults >40 Years Old with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: Single Center Outcomes

Marc Schwartz, Jonathan A Gutman, Christine M. McMahon, Maria L Amaya, Daniel A. Pollyea, Matthew Witkowski, Mohd Minhajuddin, Clayton Smith, Craig T. Jordan

Blood (2023) 142 (Supplement 1): 5898.

https://doi.org/10.1182/blood-2023-188298

Published: 2023

Journal Articles

I-DATA Study: Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-Targeted/IDH-Targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated Adult AML Patients Not Candidates for Intensive Induction Therapy

Michael P Ozga, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Jill Buss, Andrea Laganson, Ethan Hamp, Yazan F. Madanat, Daniel A. Pollyea, Eytan M. Stein, Joshua F. Zeidner, Elaine R Mardis, Ann-Kathrin Eisfeld, Alice Mims

Blood (2023) 142 (Supplement 1): 1534.

https://doi.org/10.1182/blood-2023-187060

Published: 2023

NARROW

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

STAT3-VDAC1 Axis Modulates Mitochondrial Function and Plays a Critical Role in the Survival of Leukemic Stem Cells

Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Comparison of Myeloablative Conditioning with a Total Body Irradiation-Based Regimen Versus a Chemotherapy-Based Regimen in Adult Patients Undergoing Umbilical Cord Blood Stem Cell Transplant for Ph-Negative Acute Lymphoblastic Leukemia

Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Treatment-Related and De Novo Ccus Have Similar Molecular Features and Risk of Progression to Myeloid Malignancies

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia

Targeting Mitochondrial Calcium Uptake to Eradicate Venetoclax-Resistant Acute Myeloid Leukemia Stem Cells

Age-Adapted Chemotherapy for Adults >40 Years Old with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: Single Center Outcomes

I-DATA Study: Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-Targeted/IDH-Targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated Adult AML Patients Not Candidates for Intensive Induction Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only